Abstract
Deletion of a part of the short arm of chromosome 1 is one of the most common chromosomal rearrangements observed in neuroblastoma (NBL) tumors and it is associated with a poor prognosis. No NBL tumor suppressor gene has yet been identified in the region. Our shortest region of overlap of deletions, ranging from marker D1S80 to D1S244, was shown to partly overlap a 500 kb region that was homozygously deleted in a NBL cell line. We have screened seven genes known to reside in or very close to this overlap consensus region, UBE4B/UFD2, KIF1B, DFFA, PGD, CORT, PEX14, and ICAT, for coding mutations in NBL tumor DNA. A few deviations from the reference sequences were identified; most interestingly being a splice site mutation that was detected in UBE4B/UFD2 in a stage 3 NBL with a fatal outcome. This mutation was neither present in the patients constitutional DNA nor in any of 192 control chromosomes analysed. Also, the expression of UBE4B/UFD2 was markedly diminished in the high-stage/poor-outcome tumors as compared to the low-stage/favorable-outcome tumors. Overall, the number of amino-acid changes in the genes of the region was low, which shows that mutations in these genes are rare events in NBL development. Given the data presented here, UBE4B/UFD2 stands out as the strongest candidate NBL tumor suppressor gene in the region at this stage.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Abel F, Ejeskär K, Kogner P and Martinsson T . (1999). Br. J. Cancer, 81, 1402–1409.
Abel F, Sjöberg RM, Ejeskär K, Krona C and Martinsson T . (2002). Br. J. Cancer, 86, 596–604.
Antonarakis SE . (1998). Hum. Mutat., 11, 1–3.
Bauer A, Savelyeva L, Claas A, Praml C, Berthold F and Schwab M . (2001). Genes Chromosomes Cancer, 31, 228–239.
Bown N, Cotterill S, Lastowska M, O'Neill S, Pearson AD, Plantaz D, Meddeb M, Danglot G, Brinkschmidt C, Christiansen H, Laureys G and Speleman F . (1999). N. Engl. J. Med., 340, 1954–1961.
Brodeur GM . (1990). Cancer Surv., 9, 673–688.
Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F, Kaneko M, Kemshead J, Lampert F, Lee RE, Look AT, Pearson AD, Philip T, Roald B, Sawada T, Seeger RC, Tsuchida Y and Voute PA . (1993). J. Clin. Oncol., 11, 1466–1477.
Brodeur GM, Seeger RC, Barrett A, Berthold F, Castleberry RP, D'Angio G, De Bernardi B, Evans AE, Favrot M, Freeman AI, Haase G, Hartmann O, Hayes FA, Helson L, Kemshead J, Lampert F, Ninane J, Ohkawa H, Philip T, Pinkerton CR, Pritchard J, Sawada T, Siegel S, Smith EI, Tsuchida Y and Voute PA . (1988). J. Clin. Oncol., 6, 1874–1881.
Burset M, Seledtsov IA and Solovyev VV . (2000). Nucleic Acids Res., 28, 4364–4375.
Cadigan KM and Nusse R . (1997). Genes Dev., 11, 3286–3305.
Caron H, Peter M, van Sluis P, Speleman F, de Kraker J, Laureys G, Michon J, Brugieres L, Voute PA, Westerveld A, Slater R, Delattre O and Versteeg R . (1995). Hum. Mol. Genet., 4, 535–539.
Caron H, Spieker N, Godfried M, Veenstra M, van Sluis P, de Kraker J, Voute P, and Versteeg R . (2001). Genes Chromosomes Cancer, 30, 168–174.
Clark F and Thanaraj TA . (2002). Hum. Mol. Genet., 11, 451–464.
Ejeskär K, Abel F, Sjöberg R, Backstrom J, Kogner P and Martinsson T . (2000). Cytogenet. Cell Genet., 89, 62–66.
Ejeskär K, Sjöberg RM, Abel F, Kogner P, Ambros PF and Martinsson T . (2001). Med. Pediatr. Oncol., 36, 61–66.
Guo C, White PS, Weiss MJ, Hogarty MD, Thompson PM, Stram DO, Gerbing R, Matthay KK, Seeger RC, Brodeur GM and Maris JM . (1999). Oncogene, 18, 4948–4957.
Guo C, White PS, Hogarty MD, Brodeur GM, Gerbing R, Stram DO and Maris JM . (2000) Med. Pediatr. Oncol., 35, 544–546.
Hochstrasser M . (1996). Annu. Rev. Genet., 30, 405–439.
Ichimiya S, Nimura Y, Kageyama H, Takada N, Sunahara M, Shishikura T, Nakamura Y, Sakiyama S, Seki N, Ohira M, Kaneko Y, McKeon F, Caput D and Nakagawara A . (1999). Oncogene, 18, 1061–1066.
Koegl M, Hoppe T, Schlenker S, Ulrich HD, Mayer TU and Jentsch S . (1999). Cell, 96, 635–644.
Lal S, Choi JH, Shaw JR and Hannah LC . (1999). Plant. Physiol., 121, 411–418.
Lastowska M, Cotterill S, Pearson AD, Roberts P, McGuckin A, Lewis I and Bown N . (1997). Eur. J. Cancer, 33, 1627–1633.
Liu X, Li P, Widlak P, Zou H, Luo X, Garrard WT and Wang X . (1998). Proc. Natl. Acad. Sci. USA, 95, 8461–8466.
Liu X, Zou H, Slaughter C and Wang X . (1997). Cell, 89, 175–184.
Maris JM, Guo C, Blake D, White PS, Hogarty MD, Thompson PM, Rajalingam V, Gerbing R, Stram DO, Matthay KK, Seeger RC and Brodeur GM . (2001). Med. Pediatr. Oncol., 36, 32–36.
Maris JM and Matthay KK . (1999). J. Clin. Oncol., 17, 2264–2279.
Maris JM, White PS, Beltinger CP, Sulman EP, Castleberry RP, Shuster JJ, Look AT and Brodeur GM . (1995). Cancer Res., 55, 4664–4669.
Martinsson T, Sjöberg RM, Hallstensson K, Nordling M, Hedborg F and Kogner P . (1997). Eur. J. Cancer, 33, 1997–2001.
Martinsson T, Sjöberg RM, Hedborg F and Kogner P . (1995). Cancer Res., 55, 5681–5686.
Miller JR, Hocking AM, Brown JD and Moon RT . (1999). Oncogene, 18, 7860–7872.
Ohira M, Kageyama H, Mihara M, Furuta S, Machida T, Shishikura T, Takayasu H, Islam A, Nakamura Y, Takahashi M, Tomioka N, Sakiyama S, Kaneko Y, Toyoda A, Hattori M, Sakaki Y, Ohki M, Horii A, Soeda E, Inazawa J, Seki N, Kuma H, Nozawa I and Nakagawara A . (2000). Oncogene, 19, 4302–4307.
Peifer M and Polakis P . (2000). Science, 287, 1606–1609.
Sakahira H, Enari M and Nagata S . (1999). J. Biol. Chem., 274, 15740–15744.
Sakahira H, Iwamatsu A and Nagata S . (2000). J. Biol. Chem., 275, 8091–8096.
Spieker N, Beitsma M, Van Sluis P, Chan A, Caron H and Versteeg R . (2001). Genes Chromosomes Cancer, 31, 172–181.
Tago K, Nakamura T, Nishita M, Hyodo J, Nagai S, Murata Y, Adachi S, Ohwada S, Morishita Y, Shibuya H and Akiyama T . (2000). Genes Dev., 14, 1741–1749.
Thanaraj TA and Clark F . (2001). Nucleic Acids Res., 29, 2581–2593.
White PS, Maris JM, Beltinger C, Sulman E, Marshall HN, Fujimori M, Kaufman BA, Biegel JA, Allen C, Hilliard C, Valentine MB, Look AT, Enomoto H, Sakiyama S and Brodeur GM . (1995). Proc. Natl. Acad. Sci. USA, 92, 5520–5524.
White PS, Thompson PM, Seifried BA, Sulman EP, Jensen SJ, Guo C, Maris JM, Hogarty MD, Allen C, Biegel JA, Matise TC, Gregory SG, Reynolds CP and Brodeur GM . (2001). Med. Pediatr. Oncol., 36, 37–41.
Acknowledgements
We gratefully acknowledge the financial support of the Swedish Cancer Society, the Children's Cancer Foundation, the IngaBritt and Arne Lundberg Foundation, the Assar Gabrielsson Foundation, the Wilhelm and Martina Lundgren Science Foundation and the Sahlgrenska University Hospital Foundation.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Krona, C., Ejeskär, K., Abel, F. et al. Screening for gene mutations in a 500 kb neuroblastoma tumor suppressor candidate region in chromosome 1p; mutation and stage-specific expression in UBE4B/UFD2. Oncogene 22, 2343–2351 (2003). https://doi.org/10.1038/sj.onc.1206324
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206324
Keywords
This article is cited by
-
E4 ligase–specific ubiquitination hubs coordinate DNA double-strand-break repair and apoptosis
Nature Structural & Molecular Biology (2016)
-
The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis
Pediatric Surgery International (2013)
-
Growth factor receptor trafficking as a potential therapeutic target in pediatric cancer
Frontiers in Biology (2012)
-
Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers
Nature Genetics (2010)
-
Genetic and epigenetic changes in the common 1p36 deletion in neuroblastoma tumours
British Journal of Cancer (2007)